卡培他滨、奥沙利铂联合帕博利珠单抗对进展期胃癌的疗效及安全性  

Safety and efficacy of capecitabine,oxaliplatin combined with pembrolizumab in advanced gastric cancer

作　　者：王俊松[1] 吕秀鹏[2] WANG Jun-song;Lü Xiu-peng(Department of Internal Medicine-Oncology,Dalian University Affiliated Xinhua Hospital,Dalian 116023,China;Department of Radiotherapy,the First Affiliated Hospital of Dalian Medical University,Dalian 116023,China)

机构地区：[1]大连大学附属新华医院肿瘤内科,辽宁大连116023 [2]大连医科大学附属第一医院放疗科,辽宁大连116023

出　　处：《实用药物与临床》2022年第3期217-220,共4页Practical Pharmacy and Clinical Remedies

基　　金：辽宁省自然基金指导项目(2019-ZD-0633)。

摘　　要：目的探讨帕博利珠单抗联合卡培他滨、奥沙利铂治疗进展期胃癌的临床疗效及安全性。方法以大连大学附属新华医院肿瘤内科收治的92例进展期胃癌患者为研究对象,按照随机数字法,将其分为对照组(卡培他滨+奥沙利铂,XELOX化疗,45例)和观察组(帕博利珠单抗联合XELOX化疗,47例),比较两组的临床疗效、毒副反应及生存率。结果与对照组相比,观察组患者的治疗有效率(ORR)显著升高,差异具有统计学意义(80.95%vs.67.50%);观察组患者的化疗毒副作用如白细胞减少(7.14%vs.22.50%)、血小板减少(19.04%vs.40.00%)、贫血(14.28%vs.35.00%)和甲状腺功能减退(23.81%vs.45.00%)的发生率显著低于对照组;与对照组相比,观察组无进展生存率及总生存率明显提高。结论帕博利珠单抗联合卡培他滨、奥沙利铂能够明显提高进展期胃癌患者的临床疗效,降低化疗期间的毒副反应,提升患者的生存率。Objective To investigate the safety and efficacy of capecitabine,oxaliplatin combined with pembrolizumab in advanced gastric cancers.Methods The 92 patients with advanced gastric cancer in Medical Oncology Department of Dalian University Affiliated Xinhua Hospital were randomly assigned into groups:the observational group(capecitabine+oxaliplatin combined with pembrolizumab)and the control group(capecitabine+oxaliplatin).The clinical efficacy,toxic and adverse reactions,and the survival rate in the two groups were analysed and compared.Results The observational group had statistically higher objective response rate(ORR)than the control group(80.95%vs.67.50%),and the difference was statistical.The observational group had significantly lower incidence of treatment-related adverse events including platelet count decrease(19.04%vs.40.00%),white blood cell decrease(7.14%vs.22.50%),anaemia(14.28%vs.35.00%)and hypothyroidism(23.81%vs.45.00%),than the control group.Moreover,the PFS and OS in observational group were significantly higher than those in the control group.Conclusion The treatment with capecitabine+oxaliplatin combined with pembrolizumab significantly improves the clinical efficacy in patients with advanced gastric cancer,reduces the incidence of treatment-related adverse events,and improves the patients′survival rate.

关 键 词：帕博利珠单抗 卡培他滨 奥沙利铂 进展期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]